Optimized Treatment Schedules for Chronic Myeloid Leukemia

Area of Science:

• Oncology
• Mathematical Biology
• Pharmacology

Background:

• Targeted therapies like imatinib have advanced Chronic Myeloid Leukemia (CML) treatment.
• Drug resistance, often due to pre-existing mutations, limits the long-term efficacy of CML therapies.
• Optimizing combination therapy schedules is crucial for overcoming resistance and improving patient outcomes.

Purpose of the Study:

• To develop a mathematical model for predicting CML response to combination targeted therapies.
• To analyze the impact of different treatment schedules on efficacy in patients with pre-existing resistance.
• To determine optimal combination therapy strategies that maximize time until treatment failure.

Main Methods:

• Developed an ordinary differential equation model to simulate CML dynamics under combination therapy.
• Formulated an optimization problem to identify ideal treatment schedules, considering CML evolution and drug toxicity.
• Incorporated neutrophil count dynamics to model drug toxicity constraints.
• Utilized parameters from clinical literature for hypothetical patient simulations.

Main Results:

• Identified optimal combination therapy schedules that enhance treatment efficacy against CML.
• Demonstrated the model's ability to predict treatment outcomes based on pre-existing resistance and toxicity.
• Quantified the impact of different scheduling strategies on delaying treatment failure.

Conclusions:

• Mathematical modeling provides a powerful framework for designing effective CML combination therapies.
• Optimized treatment schedules can significantly improve outcomes for CML patients, particularly those with resistance.
• This approach offers a pathway to personalized medicine by tailoring therapy based on individual patient dynamics and resistance profiles.